Ixchiq is a single shot live attenuated vaccine for the prevention of chikungunya virus vaccine which provided immunity to over 98% of participants in a phase 3 clinical trial. The vaccine was well tolerated and had an overall adverse event profile similar to other vaccines currently on the market. The Latest A 2023 phase 3
Valneva SE (NASDAQ:VALN – Get Free Report)’s share price shot up 6.1% on Thursday . The company traded as high as $8.22 and last traded at $8.22. 1,859 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 9,146 shares. The stock had previously closed at $7.75. Wall Street […]
Shares of Valneva SE (NASDAQ:VALN – Get Free Report) traded down 6.6% during trading on Tuesday . The company traded as low as $8.04 and last traded at $8.04. 2,765 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 9,495 shares. The stock had previously closed at $8.61. […]
Valneva (NASDAQ:VALN – Free Report) had its price target reduced by Guggenheim from $18.00 to $17.00 in a research note released on Friday, Benzinga reports. Guggenheim currently has a buy rating on the stock. Separately, HC Wainwright restated a buy rating and set a $26.00 target price on shares of Valneva in a research note […]
21st Austria weekly - ATX TR at 7494.85 VIG best-performing 09/03/2024 [pic1]ATX unchanged in week 10 from now on continuous auction for Austrian government bonds and International Women s Day the Vienna Stock Exchange. Bloomberg wrote that Uniqa may be targets of Italian Generali was bestperformer. News came Valneva Exchange